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summaries of their data, the ability to track their progress through a questionnaire, 
and “thank you” messages for completing frequent questionnaires. Patients would 
be motivated to complete a daily dairy by seeing their overall percent compliance to 
date. Investigators should consider including these types of elements when design-
ing ePRO assessments for clinical trials.
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Objectives: Chronic spontaneous/idiopathic urticaria (CSU/CIU) is defined as the 
spontaneous appearance of itchy hives, angioedema, or both lasting ≥ 6 weeks. CSU/
CIU has a significant yet underestimated socioeconomic impact. The ASSURE-CSU 
study aims to identify and quantify the humanistic and economic burden of CSU/
CIU. Here we present Canadian specific data on utility values. MethOds: The study 
included a retrospective medical record abstraction, a cross-sectional PRO survey, 
and 7day diary of patients with CSU/CIU still symptomatic despite treatment, aged 
≥ 18 years, with disease persisting for ≥ 12 months. Patients completed the weekly 
Urticaria Activity Score (UAS7) and the EQ-5D-3L, a 2-part instrument comprised of 
the EQ-5D and the Visual Analog Scale (VAS). ED-5D-3L and VAS utility values were 
derived using a Canadian-specific scoring algorithm and a standard UK algorithm, 
respectively. Descriptive statistics were provided for these variables and stratified 
by disease severity. Results: The cohort included 99 patients with demographics 
in line with published characteristics of CSU/CIU patients and distributed across 
severity levels. The instrument was completed by 86 patients. Overall, the mean (SD) 
EQ-5D utility score was 0.7 (0.30); while the mean (SD) VAS utility score was 71.4 
(19.24). The dimensions of the EQ-5D-3L most affected where pain/discomfort and 
anxiety/depression with 61.4% and 40.9% of patients reporting moderate to extreme 
problems, respectively. Utility values decreased with increased disease severity for 
overall and dimension specific scores for both tools. cOnclusiOns: Compared to 
the average utility score of an average Canadian population (0.875), the results of 
this study at 0.7 demonstrate that CSU/CIU has a significant impact on patients’ 
health status and quality of life; with patients suffering from moderate to severe 
urticaria showing a greater impact on patients’ health state.
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Objectives: To assess the impact of pharmacists-led non-clinical interventions on 
knowledge, attitude and perception among pulmonary tuberculosis (PTB) patients 
in Pakistan. MethOds: A randomized controlled non-clinical trial was piloted on 
PTB patients under the supervision of registered pharmacists whereby PTB patients 
received educational non-clinical interventions regarding knowledge, attitude and 
perception on PTB. Self-administered research tool was used and demographic 
characteristics of the patients were determined by means of descriptive statistics. 
Data was analyzed by using SPSS 21.0. Comparison between trial group and con-
trol group was done with the help of inferential statistics. Results: Two hundred 
and eighty PTB patients were randomly chosen for the study i.e. one hundred and 
forty in each group. No significant differences were observed in either group for 
mean age, gender, education level, occupation and income whereas a significant 
improvement (p< 0.001) in the knowledge, attitude and perception was noted in the 
interventional group. cOnclusiOns: The pharmacist-led, non-clinical interven-
tion caused a significant improvement in PTB patients’ knowledge, attitude and 
perception scores. This study highlights pharmacists’ need and their significantly 
important role towards better patient care and education. These finding are con-
siderably useful for better disease management and control.
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Objectives: The purpose of this study was to examine the treatment outcomes of 
smear positive pulmonary TB cases registered in TB patients in Quetta. MethOds: 
Cross sectional retrospective cohort study was performed on TB patient in Fatima 
Jinnah chest hospital, Quetta. Retrospective medical records of smear-positive 
tuberculosis patients registered in first quarter of year 2012. Tuberculosis treatment 
outcomes were assessed according to WHO guidelines. The descriptive statistics 
was used to present the demographic and disease related information. Inferential 
statistics was used to the evaluation relationship among study variables. All anal-
yses were performed using SPSS 20.0. Results: Out of the 131 TB patients (67 
males and 64 females). Majority of the patients were in the age group 18-47 (73.7%). 
High percentage of the patients had successful treatment with treatment outcome 
“Completed” and ‟cured” were 65.5% (n= 74), whereas, death occurred in only 5.3% 
(n= 7) of patients. Demographic characteristics age was the only determine factor 
Objectives: Chronic spontaneous/idiopathic urticaria (CSU/CIU) is defined as the 
spontaneous appearance of itchy hives, angioedema, or both lasting ≥ 6 weeks. CSU/
CIU has a significant yet underestimated impact on patient’s work productivity. The 
ASSURE-CSU study aims to identify and quantify the humanistic and economic 
burden of CSU/CIU. Here we present Canadian data on work productivity and indi-
rect costs. MethOds: Patients with CSU/CIU, aged ≥ 18 years, with disease for ≥ 12 
months, symptomatic despite treatment were recruited in the study. Data were col-
lected on absenteeism and productivity loss via the Work Productivity and Activity 
Impairment –Specific Health problem (WPAI-SHP) questionnaire. The associated 
indirectly monthly costs were estimated based on 150hr/working week and average 
wage $CAD 25.62/hr. Descriptive statistics were provided and stratified by disease 
severity. Results: Cohort included 99 patients with a mean age of 50.8 years; 5 years 
mean disease duration, and a higher proportion of women (77.8%). Overall, 86 patients 
completed the WPAI with 54.7% employed (assessed separately from the WPAI, 46.5% 
had full-time employment). In the last 7 days, the mean proportion of time missed at 
work due to CSU/CIU was 6.0% (SD= 12.0%). The greatest percentage of time missed 
due to CSU/CIU was reported in moderate and severe patients (8.9% and 10.6%, respec-
tively). The mean proportion of overall work impairment due to CIU/CSU was 30.6% 
(SD= 27%). Total indirect monthly cost of work productivity loss was estimated to be 
a mean (SD) of $1,177 per patient in full-time employment. The overall indirect costs 
increased with disease severity. cOnclusiOns: This Canadian-specific analysis from 
ASSURE-CSU suggests that almost all patients in employment are affected at work by 
their disease, either through absenteeism or reduced productivity at work resulting 
in significant economic impact for employers and society.
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Objectives: Compare healthcare resource utilization of patients with severe 
asthma and elevated blood eosinophils (EOS) versus normal EOS. MethOds: 
Asthma patients were extracted from EMRClaims+ database from Jan 2004-July 
2011. Date of asthma diagnosis was defined as the index date. The 12-month 
period following index was defined as ‘assessment’ period, with disease severity 
classified by factors such as medication use and lung function based on the newly 
published European Respiratory Society/American Thoracic Society guidelines. 
Patients with ‘severe’ asthma were classified as those with ‘elevated’ (≥ 400 cells/
µL) and ‘normal’ EOS (< 400 cells/µL). Patients were followed for a maximum 
period of 12 months after index to record all-cause hospitalizations, ER and out-
patient visits and associated costs. Mean hospitalizations, visits, and costs were 
compared using Wilcoxon signed rank test. Proportions were compared using Chi 
square tests. Logistic regression was conducted to assess the influence of elevated 
EOS on probability of incurring resource use after controlling for demographics 
and baseline comorbidities. Results: Of the 2,164 asthma patients identified, 
184 (9%) were concordant with guideline recommendation for medication use for 
severe asthma (Guideline-Concordant-Severe: GCS patients). Of these, 56 (30%) 
had elevated EOS. A significantly greater proportion of GCS patients with elevated 
EOS had admissions during follow-up compared to those with normal EOS (29% 
vs 13%, p= 0.013). GCS patients with elevated EOS had significantly greater mean 
monthly admissions compared to normal EOS patients (0.1 vs 0.02, p= 0.011) and 
8 times the hospitalization cost compared to the group with normal EOS [$834 
(SD:4403) vs. $106 (SD:336), p= 0.012]. Logistic regression showed that patients 
with elevated EOS had greater likelihood of admissions during follow-up (OR: 2.61, 
p= .033). cOnclusiOns: Among patients with severe asthma with treatments 
concordant with ERS/ATS guidelines, those with elevated EOS experienced more 
frequent hospital admissions and greater cost compared to those with normal EOS.
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Objectives: Clinical trials for COPD are increasingly using electronic methods 
to collect patient-reported outcomes (ePRO). As use of this technology increases, 
it is important to consider patient preference in questionnaire design. This study 
examined patient preference for receiving real-time feedback while completing 
ePRO assessments. MethOds: A total of 103 patients with COPD were surveyed. 
Patients were asked to assume that they were using a handheld or tablet device to 
complete questionnaires as part of a clinical trial; they were then presented with 
example screens and asked about types of feedback they might receive on the 
device. Results: Patients ranged in age from 32 to 86 years and were 55% female. 
50% reported previous participation in a clinical trial. 59% reported that they would 
like to see a “thank you” screen at the end of each questionnaire. 81% thought 
it would be helpful or necessary to regularly receive a graph summarizing their 
responses. 81% preferred to see their progress as they completed a questionnaire; of 
these, 41% preferred a progress bar and “Question X of X” message and 47% preferred 
just the progress bar. 69% said they would like the first screen to summarize the 
questionnaire’s length and estimated completion time. Regarding feedback about 
daily diary compliance, 76% reported that a summary screen showing their percent 
compliance would motivate them to complete their diary each day. cOnclusiOns: 
Patients with COPD prefer to receive real-time feedback while completing ePRO 
assessments, and are motivated by compliance information. Specifically, they prefer 
